Paper Review Records
全部论文审稿周期
20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
206
天
Decoding glioblastoma evolution and heterogeneity through mechanistic modeling: implications for clinical translation
作者
Haowu Jiang; Wan Zhao; Hui Zhou; Rui Sun展开收起
作者单位
1. Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Hefei National Research Center for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s Republic of China; 2. Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s Republic of China; 3. Department of Respiratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, People’s Republic of China; 4. Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, People’s Republic of China展开收起
160
天
From paradox to target: IFN-β hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancer
作者
Yangyang Zhou; Haigang Geng; Yi Xu; Yanggang Hong; Bo Mei; Huanglei Wu; Xuanxuan Jin; Mengfan Ye; Yi Wang; Zan Shen; Zhigang Zheng; Zhenhua Zhu; Xiangchou Yang; Zizhen Zhang; Chunchao Zhu展开收起
作者单位
1. Department of Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2. Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 3. Department of Gastrointestinal Cancer Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China; 4. State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 5. The Second School of Medicine, Wenzhou Medical University, Wenzhou, China; 6. Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Beijing, China; 7. Department of Coloprotology, The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; 8. Department of Urology, The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; 9. The First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, China; 10. Shanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 11. Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 12. Department of Hematology and Medical Oncology, The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China展开收起
206
天
HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma
作者
Alvin Ho Kwan Cheung; Kit Yee Wong; Gordon Yuan-Ho Li; Fuda Xie; Qiuqiu Wu; Thomas Tin Ho Yuen; Pak Lam Hui; Pingmei Huang; Xiaoli Liu; Bonan Chen; Fenfen Ji; Yujuan Dong; Alfred Sze-Lok Cheng; Calvin Sze Hang Ng; Xiang Zhang; Chi Chun Wong; Jun Yu; Wei Kang; Ka-Fai To展开收起
作者单位
1. Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2. Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; 3. Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 4. School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China展开收起
32
天
Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer
作者
Maximilian Hellkamp; Simon Gertken; Jonas Buchloh; Julius-Leonard Hellwig; Lukas Ben Kowitzke; Ningjun Duan; Ilaria Gaspardo; Stefan Küffer; Michael Linnebacher; Philipp Ströbel; Matthias Wirth; Volker Ellenrieder; Stefan Rieken; Jochen Gaedcke; Michael Ghadimi; Jürgen Wienands; Günter Schneider; Melanie Spitzner; Marian Grade展开收起
作者单位
1. Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany; 2. Research Training Group (RTG) 2978, University Medical Center Göttingen, Göttingen, Germany; 3. Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; 4. Molecular Oncology and Immunotherapy, Clinic of General Surgery, University Medical Center Rostock, Rostock, Germany; 5. CCC-N (Comprehensive Cancer Center Lower Saxony), Göttingen, Germany; 6. Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 7. Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Germany; 8. Department of Radiotherapy and Radiooncology, University Medical Center Göttingen, Göttingen, Germany; 9. Clinic for General and Visceral Surgery, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany; 10. Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany; 11. Institute for Translational Cancer Research and Experimental Cancer Therapy, Technical University Munich, Munich, Germany展开收起
128
天
Cellular immunotherapy in melanoma: the next frontier in cancer treatment
作者
Anna-Lena Wien; Angeliki Stamtsis-Datsi展开收起
作者单位
1. Institute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany展开收起
108
天
Loss of CSE couples with BRAF V600E to fuel thyroid cancer metastatic progression through zinc-dependent activation of the EMT machinery
作者
Shichen Xu; Huixin Yu; Hongxun Wu; Zongfu Pan; Jiajie Xu; Yun Zhu; Botao Huang; Gangming Cai; Xiaobo Gu; Min Yang; Donghui Pan; Jie Pan; Jing Wu; Xian Cheng; Jiandong Bao; Li Zhang展开收起
作者单位
1. National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China; 2. Jiangsu Institute of Nuclear Medicine Jiangyuan Hospital of Jiangsu Province, Wuxi, China; 3. Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China; 4. Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People’s Hospital, Hangzhou, China; 5. Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, China; 6. School of Life Sciences, Nanjing Medical University, Changzhou, China; 7. School of Life science and Technology, Southeast University, Nanjing, China展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天